within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC03_Bezlotoxumab;

model Bezlotoxumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.6689814814814816e-09,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.00733,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00331,
    k12 = 3.6458333333333333e-09,
    k21 = 3.6458333333333333e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bezlotoxumab</td></tr><tr><td>ATC code:</td><td>J06BC03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>7.33</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.317</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bezlotoxumab is a human monoclonal antibody that binds to Clostridioides difficile toxin B and is indicated for the prevention of recurrent C. difficile infection in adults at high risk. It is administered as a single intravenous infusion and is currently approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with C. difficile infection, primarily males and females aged 18–100 years, without significant hepatic or renal impairment.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J06BC03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bezlotoxumab;
